Biogen, OMRF partner in Sjogren's syndrome
Biogen Inc. and the Oklahoma Medical Research Foundation (OMRF) are teaming up to discover biomarkers that can be...
Welcome to Scrip
Create an account to read this article
Already a subscriber?
Tech Transfer Deals, November 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.
More from Deals
• By
Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.
• By
With Sidley attorney Robert Darwin and EY economic analyst Arda Ural, Scrip looked at recent deals, the potential for more deals in the obesity space, and what type of assets might be most in demand.
• By
The big pharma remains committed to buying Metsera, even as the acquisition price has grown and some analysts pressed management on the value of the deal.
• By
Pfizer filed another lawsuit to halt Novo Nordisk’s attempt to acquire obesity drug developer Metsera instead of the US big pharma. Novo said Pfizer’s legal actions are “without merit” and “desperate.”
More from Business
• By
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
• By
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
• By
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.